Genitourinary Cancers | Specialty

Figlin Views Combination Therapy as the Key to Durable Responses in RCC

March 16th 2016

Robert A. Figlin, MD, FACP, discusses how the genomics of kidney cancer have evolved over recent years.

FDA Grants Atezolizumab Priority Review in Bladder Cancer

March 15th 2016

The FDA has granted a priority review to atezolizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy in the metastatic setting, or whose disease worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.

Atezolizumab Approaches FDA Approval in Bladder Cancer, But Biomarkers Remain Unclear

March 15th 2016

Matthew Galsky, MD, explains the challenges of utilizing molecular subtyping and PD-L1 as biomarkers, the impact a potential approval of atezolizumab could have in metastatic bladder cancer, possible combinations that could increase ORR, and next steps in understanding the IMvigor study.

Dr. Gulley on Checkpoint Inhibitors in Bladder Cancer

March 14th 2016

James L. Gulley, MD, PhD, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, National Cancer Institute, discusses checkpoint inhibitors in bladder cancer.

Kidney Cancer Genomic Studies Reveal New Targets and Complexities

March 14th 2016

Genome sequencing studies are beginning to match distinct genomic profiles to different subtypes of kidney cancer, driving a dramatic shift in our understanding of these diseases and how to treat them.

Nivolumab Practice-Changing in RCC, But Biomarkers Still Critical for Progress

March 9th 2016

Jorge Garcia, MD, discusses CheckMate-025, the challenges with PD-1 as a biomarker, additional potential biomarkers, and why combination immunotherapy in renal cell carcinoma is still a work in progress.

Dr. Srinivasan on Targeted Therapies for Non-Clear Cell RCC

February 23rd 2016

Ramaprasad Srinivasan, MD, PhD, staff clinician, Urologic Oncology Branch, National Cancer Institute, discusses the need for targeted therapies for patients with non-clear cell renal cell carcinoma (RCC) and the types of agents these patients are likely benefit to from.

Durvalumab Granted Breakthrough Status for Bladder Cancer

February 17th 2016

The FDA has granted a breakthrough therapy designation to durvalumab as a treatment for patients with PD-L1–positive inoperable or metastatic urothelial bladder cancer following progression on prior treatment with a platinum-based regimen.

Expert Discusses Exciting Potential for Atezolizumab in Bladder Cancer

February 15th 2016

Arjun V. Balar, MD, discusses the phase II data demonstrating the efficacy of atezolizumab as a single agent, its potential as part of combination regimens, and planned clinical trials looking at immunotherapy in patients with metastatic bladder cancer.

Nivolumab, Cabozantinib Offer New Second-Line Options in RCC

February 15th 2016

Toni Choueiri, MD, discusses the CheckMate-025 and METEOR trials and the potential for nivolumab and cabozantinib in the first- and second-line settings for treating renal cell carcinoma.

Dr. Sharma on PD-L1 as Biomarker for Immunotherapy in Bladder Cancer

February 12th 2016

Padmanee Sharma, MD, PhD, professor of Immunology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses PD-L1 as a predictive biomarker for immunotherapy in patients with bladder cancer.

First Urology of Louisville Enjoys Many Firsts in Technology and Research

February 9th 2016

Being the largest private practice urology center in Kentucky has its advantages, said Ganesh Rao, MD, president of First Urology, PSC, in Louisville.

Patient-Derived Xenografts Could Improve Precision Medicine Outcomes

February 6th 2016

Researchers at the UC Davis Comprehensive Cancer Center are personalizing treatment using tumor xenografts in mice to test and identify more precise treatments for bladder cancer patients.

Future Expectations in Renal Cell Carcinoma

February 4th 2016

Sequencing Metastatic Renal Cell Carcinoma Treatments

February 4th 2016

The Role of Lenvatinib and Cabozantinib in RCC

February 4th 2016

Sequencing Renal Cell Carcinoma Therapies

February 4th 2016

Managing Checkpoint Inhibitor Therapy in RCC

February 4th 2016

Study Results of Nivolumab in Renal Cell Carcinoma

February 4th 2016

Defining Disease Progression in Renal Cell Carcinoma

February 4th 2016